Acute Bacterial Skin and Skin Structure Infections - Pipeline Insight, 2021
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Acute Bacterial Skin and Skin Structure Infections - Pipeline Insight, 2021,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Acute Bacterial Skin and Skin Structure Infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Acute Bacterial Skin and Skin Structure Infections: Overview
Acute Bacterial Skin and Skin Structure Infection is a bacterial infection of the skin and associated tissues. The FDA defines skin and skin structure infections as an acute bacterial skin and skin structure infection or ABSSSI if the infection is accompanied by redness, edema, and/or induration of a minimum surface area of 75 cm2, accompanied by lymph node enlargement or systemic symptoms such as fever ?38°C (100.4°F). Some of the most common bacterial pathogens that cause Acute Bacterial Skin and Skin Structure Infections are Streptococcus pyogenes and Staphylococcus aureus, including methicillin-resistant S.aureus. Less common causes include other Streptococcus species, Enterococcus faecalis, or Gram Negative bacteria.
'Acute Bacterial Skin and Skin Structure Infections - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acute Bacterial Skin and Skin Structure Infections pipeline landscape is provided which includes the disease overview and Acute Bacterial Skin and Skin Structure Infections treatment guidelines. The assessment part of the report embraces, in depth Acute Bacterial Skin and Skin Structure Infections commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acute Bacterial Skin and Skin Structure Infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Acute Bacterial Skin and Skin Structure Infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Acute Bacterial Skin and Skin Structure Infections Emerging Drugs
Further product details are provided in the report……..
Acute Bacterial Skin and Skin Structure Infections: Therapeutic Assessment
This segment of the report provides insights about the different Acute Bacterial Skin and Skin Structure Infections drugs segregated based on following parameters that define the scope of the report, such as:
Acute Bacterial Skin and Skin Structure Infections: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Acute Bacterial Skin and Skin Structure Infections therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acute Bacterial Skin and Skin Structure Infections drugs.
Acute Bacterial Skin and Skin Structure Infections Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Acute Bacterial Skin and Skin Structure Infections - Pipeline Insight, 2021,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Acute Bacterial Skin and Skin Structure Infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Acute Bacterial Skin and Skin Structure Infections: Overview
Acute Bacterial Skin and Skin Structure Infection is a bacterial infection of the skin and associated tissues. The FDA defines skin and skin structure infections as an acute bacterial skin and skin structure infection or ABSSSI if the infection is accompanied by redness, edema, and/or induration of a minimum surface area of 75 cm2, accompanied by lymph node enlargement or systemic symptoms such as fever ?38°C (100.4°F). Some of the most common bacterial pathogens that cause Acute Bacterial Skin and Skin Structure Infections are Streptococcus pyogenes and Staphylococcus aureus, including methicillin-resistant S.aureus. Less common causes include other Streptococcus species, Enterococcus faecalis, or Gram Negative bacteria.
'Acute Bacterial Skin and Skin Structure Infections - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acute Bacterial Skin and Skin Structure Infections pipeline landscape is provided which includes the disease overview and Acute Bacterial Skin and Skin Structure Infections treatment guidelines. The assessment part of the report embraces, in depth Acute Bacterial Skin and Skin Structure Infections commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acute Bacterial Skin and Skin Structure Infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Acute Bacterial Skin and Skin Structure Infections R&D. The therapies under development are focused on novel approaches to treat/improve Acute Bacterial Skin and Skin Structure Infections.
This segment of the Acute Bacterial Skin and Skin Structure Infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Acute Bacterial Skin and Skin Structure Infections Emerging Drugs
- Zevtera: Basilea Pharmaceutica
- Contezolid acefosamil: MicuRx Pharmaceuticals
Further product details are provided in the report……..
Acute Bacterial Skin and Skin Structure Infections: Therapeutic Assessment
This segment of the report provides insights about the different Acute Bacterial Skin and Skin Structure Infections drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Acute Bacterial Skin and Skin Structure Infections
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intradermal
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Acute Bacterial Skin and Skin Structure Infections: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Acute Bacterial Skin and Skin Structure Infections therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acute Bacterial Skin and Skin Structure Infections drugs.
Acute Bacterial Skin and Skin Structure Infections Report Insights
- Acute Bacterial Skin and Skin Structure Infections Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Acute Bacterial Skin and Skin Structure Infections drugs?
- How many Acute Bacterial Skin and Skin Structure Infections drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acute Bacterial Skin and Skin Structure Infections?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Acute Bacterial Skin and Skin Structure Infections therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Acute Bacterial Skin and Skin Structure Infections and their status?
- What are the key designations that have been granted to the emerging drugs?
- Basilea Pharmaceutica
- MicuRx Pharmaceuticals
- TenNor Therapeutics Limited
- GlaxoSmithKline
- Debiopharm Group
- Innovation Pharmaceuticals, Inc.
- Botanix pharmaceuticals
- Taxis Pharmaceuticals
- Zevtera
- Contezolid acefosamil
- TNP-2092
- GSK2140944
- Debio 1452
- Brilacidin
- TXA709
Introduction
Executive Summary
Acute Bacterial Skin and Skin Structure Infections: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Zevtera: Basilea Pharmaceutica
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Brilacidin: Innovation Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
TXA709: Taxis Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
Cannabidiol: Botanix pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Acute Bacterial Skin and Skin Structure Infections Key Companies
Acute Bacterial Skin and Skin Structure Infections Key Products
Acute Bacterial Skin and Skin Structure Infections- Unmet Needs
Acute Bacterial Skin and Skin Structure Infections- Market Drivers and Barriers
Acute Bacterial Skin and Skin Structure Infections- Future Perspectives and Conclusion
Acute Bacterial Skin and Skin Structure Infections Analyst Views
Acute Bacterial Skin and Skin Structure Infections Key Companies
Appendix
Executive Summary
Acute Bacterial Skin and Skin Structure Infections: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Zevtera: Basilea Pharmaceutica
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Brilacidin: Innovation Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
TXA709: Taxis Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
Cannabidiol: Botanix pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Acute Bacterial Skin and Skin Structure Infections Key Companies
Acute Bacterial Skin and Skin Structure Infections Key Products
Acute Bacterial Skin and Skin Structure Infections- Unmet Needs
Acute Bacterial Skin and Skin Structure Infections- Market Drivers and Barriers
Acute Bacterial Skin and Skin Structure Infections- Future Perspectives and Conclusion
Acute Bacterial Skin and Skin Structure Infections Analyst Views
Acute Bacterial Skin and Skin Structure Infections Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Acute Bacterial Skin and Skin Structure Infections
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Acute Bacterial Skin and Skin Structure Infections
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Acute Bacterial Skin and Skin Structure Infections
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Acute Bacterial Skin and Skin Structure Infections
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
